Hims & Hers Health (NYSE:HIMS) Stock Price Expected to Rise, TD Cowen Analyst Says

Hims & Hers Health (NYSE:HIMS) had its price objective raised by equities researchers at TD Cowen from $25.00 to $28.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price objective would suggest a potential upside of 24.94% from the stock’s current price.

A number of other brokerages have also recently weighed in on HIMS. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday. Piper Sandler reissued a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday. Finally, Truist Financial raised their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and an average price target of $21.21.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded down $1.21 during mid-day trading on Friday, reaching $22.41. The company’s stock had a trading volume of 11,658,064 shares, compared to its average volume of 8,651,810. The stock has a 50-day moving average of $18.57 and a two-hundred day moving average of $18.33. The stock has a market capitalization of $4.81 billion, a P/E ratio of 50.84 and a beta of 1.06. Hims & Hers Health has a 1-year low of $6.58 and a 1-year high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The firm had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period last year, the business earned ($0.04) earnings per share. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. Analysts predict that Hims & Hers Health will post 0.22 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total value of $38,593.50. Following the sale, the insider now directly owns 176,952 shares in the company, valued at approximately $2,919,708. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total value of $38,593.50. Following the sale, the insider now directly owns 176,952 shares in the company, valued at approximately $2,919,708. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the sale, the chief financial officer now owns 145,763 shares in the company, valued at approximately $2,960,446.53. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 854,547 shares of company stock worth $15,987,230 over the last ninety days. 17.71% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently bought and sold shares of the stock. Quest Partners LLC increased its stake in Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares in the last quarter. Royce & Associates LP grew its stake in Hims & Hers Health by 17.0% during the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares in the last quarter. Victory Capital Management Inc. grew its stake in Hims & Hers Health by 164.9% during the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock valued at $950,000 after acquiring an additional 32,108 shares in the last quarter. WealthPlan Investment Management LLC purchased a new position in Hims & Hers Health during the 3rd quarter valued at about $1,042,000. Finally, Versor Investments LP purchased a new position in Hims & Hers Health during the 3rd quarter valued at about $634,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.